BC3 TECHNOLOGIES SEAL HEMOSTATIC WOUND SPRAY APPROVED TO BE UTILIZED BY MARYLAND EMS CLINICIANS
For Immediate Release
January 9, 2025
Contact: Nicole Halsey/Natalie Halsey
Polished Nichols Public Relations & Marketing
nicole@polishednichols.com
natalie@polishednichols.com
BC3 TECHNOLOGIES SEAL HEMOSTATIC WOUND SPRAY APPROVED TO BE UTILIZED BY MARYLAND EMS CLINICIANS
– MIEMSS Permits All FDA-Approved and FDA-Cleared Chitosan Hemostatic Agents –
Baltimore, MD, January 9, 2025 — BC3 Technologies, a Baltimore-based, minority-owned company revolutionizing emergency medical response and trauma care, announces today that its SEAL hemostatic wound spray can now be used by Maryland EMS clinicians to help stop blood loss fast.
In December 2024, the Maryland Institute of Emergency Medical Services Systems (MIEMSS) declared all FDA-approved/FDA-cleared chitosan or kaolin based hemostatic agents will be permitted in Maryland for the purposes of hemorrhage control.
“We recognize that hemorrhage control for injured patients is of paramount importance. Whether the bleeding is controlled with a gloved hand, gauze, or a tourniquet, every minute counts for the patients,” said Timothy Chizmar, MD, State EMS Medical Director, MIEMSS.
While some bleeding can be controlled by hand or gauze, many wounds prove to be more challenging to manage. MIEMSS and other groups of experts in trauma surgery and emergency medicine reviewed hemostatic agents in various forms including powder and spray that are currently available to the EMS community.
“We are fortunate that Maryland is a forward-leaning, highly data-driven EMS system. With alterations and adjustments to protocol or EMS initiatives based on positive patient outcomes. MIEMSS examined our research, along with deployments internationally, and provided products to the University of Maryland Shock Trauma Center. They analyzed the data from our studies and FDA clearance documents, validated our products, and informed MIEMSS that SEAL was acceptable for trauma care in Maryland,” shared Wayne Grube, CEO and Co-Founder, BC3 Technologies.
“As a result of the assessment, Maryland EMS clinicians may now utilize a chitosan- or kaolin-based hemostatic agent, which is FDA-approved or FDA-cleared, for hemorrhage control. The hemostatic agent may be embedded in gauze or packaged in another form (e.g. spray or gel). Individual hemostatic products should be reviewed with county or service medical directors prior to implementation,” included Chizmar. Now all Maryland EMS clinicians have consent to utilize SEAL as part of their protocols to stop blood loss fast.
“This protocol change opens many doors for BC3 Technologies. Maryland is leading the way in improving patient outcomes by seeing SEAL as the innovative breakthrough that will save lives. With a Maryland EMS deployment, we are encouraging others to follow,” shared Grube.
SEAL Hemostatic Would Spray is the first and only FDA-cleared aerosolized chitosan for rapid management of serious arterial bleeding. Marking a significant advancement in emergency medical response and trauma care, SEAL is an innovative patent-pending product that acts as a strong physical barrier, effectively and quickly sealing wounds to stop blood flow within seconds. Unlike bandage or granule-based chitosan products, SEAL can be applied under windy and wet conditions and in low-light. The product is compact, easy to carry, and can be administered by first responders, professional medical staff, military, patients, or caregivers. SEAL Pro is available as a 2.5 oz single use spray and SEAL OTC a 1.5 oz single use spray. BC3 Technologies offers First Aid Only First Aid Kit with SEAL and MOLLE Pouches with tourniquet and trauma shears.
About BC3 Technologies (www.bc3tech.com)
Founded in Baltimore in 2018, BC3 Technologies is a minority-owned company revolutionizing emergency medical response and trauma care. A privately held medical device company, BC3 Technologies focuses on the development and commercialization of hemostatic products that help save lives. Fueled by the recognition of a critical gap in emergency medical care and the urgent need for efficient management of life-threatening arterial bleeding, the company designed its patent-pending technology in the first and only FDA-cleared chitosan aerosol hemostatic wound spray, SEAL. Today, SEAL is being utilized by first responders, in surgical environments, and in battlefield combat globally.
###
